Hypophosphatasia (HPP) is a rare genetic condition due to ALPL loss-of-function mutations. The broad phenotypic spectrum ranges from absence of bone mineralisation and in-utero fetal death to mild musculoskeletal disturbances in adulthood. For those most severely affected, enzyme replacement therapy with asfotase alfa in combination with a multidisciplinary approach at any age can be life-changing.